Compare Heron Therapeutics Inc (HRTX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs SYSCO Corporation — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while SYSCO Corporation trades at $81.27 (market cap $38.63B). The key difference: SYSCO Corporation is far larger — about 422.4× Heron Therapeutics Inc's market cap, and SYSCO Corporation pays a 2.72% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SYY | |
|---|---|---|
Market Cap | $91.46M | $38.63B |
Sector | Health | Consumer Staples |
52-Week High | $1.96 | $91.16 |
52-Week Low | $0.39 | $69.30 |
Enterprise Value | $189.36M | $52.11B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
SYY trades at $81.02, down 0.82% on the day, with a neutral technical signal and support at $81. The company reported $81.37B in revenue for 2025 with a net margin of 2.08%, and upcoming Q4 2026 earnings on August 4 are expected at $1.51 EPS. Positive cash flow trends and a dividend of $0.55 payable July 24 provide stability, while analyst consensus is bullish with a $84.75 price target.
Outlook is cautiously optimistic given analyst buy ratings (60%) and steady revenue growth, but risks include thin profit margins and high debt levels. The stock offers value with a P/S of 0.47, though near-term performance hinges on earnings results and macroeconomic conditions affecting the food distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
